Revenue growth was primarily driven by a 29% year-over-year increase in commercial cell and gene therapy support, which now represents 20% of total revenue.

The company maintains a dominant market position, supporting approximately 70% of all cell and gene therapy industry clinical trials.

Management describes the clinical pipeline as 'spring-loaded' for future commercial revenue, with 86 trials in Phase III and 361 in Phase II.

Operational discipline and cost reduction initiatives resulted in a $12 million year-over-year improvement in adjusted EBITDA and a 47% gross margin.

The strategic sale of CRYOPDP to DHL provided a substantial capital infusion and established a partnership to leverage DHL's global scale in APAC and EMEA regions.

Strategic collaborations with Cardinal Health and Parexel aim to standardize supply chain solutions and embed Cryoport deeper into the life sciences ecosystem.

Internal investments focused on expanding global infrastructure, including new supply chain centers in Paris and California to support commercial client scaling.

Full year 2026 revenue guidance is set at $190 million to $194 million, characterized by management as an appropriate starting point given macro volatility.

Management anticipates achieving positive adjusted EBITDA in the second half of 2026 as recent infrastructure investments begin to scale.

The outlook assumes significant regulatory activity, including 13 BLA or MAA filings and 9 new therapy approvals expected within the year.

Growth in the Life Sciences Products segment is projected at mid-to-high single digits, supported by the launch of the Fusion 800 Series self-sustaining cryogenic freezer.

The transition of therapies to outpatient community care settings is expected to serve as a significant long-term volume driver for commercial services.

CRYOPDP financials are now presented as discontinued operations following the strategic partnership and sale to DHL Group.

The timeline for positive adjusted EBITDA was shifted to late 2026 to accommodate accelerated investments in specific client-requested infrastructure, such as the Belgium facility.

Management noted that while biopharma funding saw a strong recovery in late 2025, there is typically a half-year lag before this impacts order volume.

Geopolitical tensions have had minimal impact on operations to date, with no expected flight cancellations or major disruptions in the near term.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Commercial therapy remains the primary growth engine, though management declined to provide specific percentage composition for the 2026 guide.

Life Sciences Services are expected to maintain double-digit growth, while Products (MVE) are projected for mid-to-high single-digit growth.

Profitability will be driven by scaling existing infrastructure and capturing efficiencies rather than further aggressive cost-cutting.

Management emphasized remaining opportunistic, citing the rapid build-out of the Belgium site for a large commercial account as a necessary short-term investment for long-term gain.

Management views the potential shift toward single pivotal trials as a positive catalyst for streamlining the path to commercialization.

The removal of REMS requirements is viewed as a 'huge driver' that allows clients to expand therapy access into community care settings.

While specific 5-year percentages were not provided, management expects commercial cell and gene therapy to become the 'dominant factor' in total revenue.

As commercial approvals accelerate, Cryoport's overall growth rate is expected to align more closely with the high-growth cell and gene therapy industry.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.